Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.12.28.21268481: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Human subjects and sampling: Human plasma samples obtained from vaccinated health care workers without infection, who received two doses of BNT162b2 (Pfizer/BioNTech) mRNA vaccine, were collected on approximately day 51 and day 161 after the first vaccination, with written informed consent prior to enrollment and ethics approval by the medical research ethics committee of the National Institute of Infectious Diseases (NIID) for the use of human subjects (#1321).
IRB: Human subjects and sampling: Human plasma samples obtained from vaccinated health care workers without infection, who received two doses of BNT162b2 (Pfizer/BioNTech) mRNA vaccine, were collected on approximately day …SciScore for 10.1101/2021.12.28.21268481: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Human subjects and sampling: Human plasma samples obtained from vaccinated health care workers without infection, who received two doses of BNT162b2 (Pfizer/BioNTech) mRNA vaccine, were collected on approximately day 51 and day 161 after the first vaccination, with written informed consent prior to enrollment and ethics approval by the medical research ethics committee of the National Institute of Infectious Diseases (NIID) for the use of human subjects (#1321).
IRB: Human subjects and sampling: Human plasma samples obtained from vaccinated health care workers without infection, who received two doses of BNT162b2 (Pfizer/BioNTech) mRNA vaccine, were collected on approximately day 51 and day 161 after the first vaccination, with written informed consent prior to enrollment and ethics approval by the medical research ethics committee of the National Institute of Infectious Diseases (NIID) for the use of human subjects (#1321).Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources VeroE6/TMPRSS2 cells (JCRB1819, Japanese Collection of Research Bioresources Cell Bank) were maintained in low glucose DMEM (Fujifilm) containing 10% heat-inactivated fetal bovine serum (Biowest), 1 mg/mL geneticin (Thermo Fisher Scientific), and 100 U/mL penicillin/streptomycin (Thermo Fisher Scientific) at 37°C supplied with 5% CO2. VeroE6/TMPRSS2suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)293T cells transfected with expression plasmids encoding the spike genes of SARS-CoV-2 ancestral strain, D614G, Beta, Delta, and Omicron variants were infected with G-complemented VSVΔG/Luc. 293Tsuggested: NoneRecombinant DNA Sentences Resources Recombinant RBD antigens: Human codon-optimized sequences coding the SARS-CoV-2 RBD (amino acids: 331-529) with the following mutations were cloned into the mammalian expression vector pCAGGS: Beta, K417N / E484K / N501Y; Delta, L452R / T478K; Omicron, G339D / S371L / S373P / S375F / K417N / N440K / G446S / S477N / T478K / E484A / Q493R / G496S / Q498R / N501Y / Y505H. pCAGGSsuggested: RRID:Addgene_127347)Recombinant Avi-tagged His-tagged proteins were produced using Expi293F cells, according to the manufacturer’s instructions (Thermo Fisher Scientific), in the presence of the secreted BirA-Flag plasmid (Addgene) and biotin. BirA-Flagsuggested: RRID:Addgene_64395)Software and Algorithms Sentences Resources Statistical analysis: Data analysis and visualization were performed using GraphPad Prism software. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This study had several limitations. First, the number of samples evaluated was small. Second, since sera from vaccine recipients without breakthrough infection at 6 months after vaccination had a low neutralization titer even against the ancestral virus in our assay, an accurate fold-reduction in neutralizing antibody titer could not be determined. Third, we did not include serum samples collected immediately (<10 days) after breakthrough infection. It is expected that the longer the interval between the vaccine and infection, the lower the antibody titer at the time of breakthrough infection. The possibility that reduced neutralizing activity at the time of breakthrough infection results in efficient viral replication in the upper respiratory tract, which may contribute to a better antibody response, was not evaluated in the present study. Fourth, we did not assess T cell immunity against SARS-CoV-2, including the Omicron variant, which contributes to protection when antibody titers are low in non-human primate models (McMahan et al., 2021) and may correlate with protection against severe disease. Finally, our investigation did not evaluate the actual risk of reinfection by the Omicron variant in individuals with a history of breakthrough infection. In conclusion, breakthrough sera demonstrated improved cross-neutralization against the Omicron variant, and the time from vaccination to breakthrough infection was a key determinant of the magnitude and breadth of neutralizing a...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
